Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant

Larisa Broglie*, Irene Helenowski, Lawrence J Jennings, Kristian Schafernak, Reggie E Duerst, Jennifer Schneiderman, William T Tse, Morris Kletzel, Sonali Chaudhury

*Corresponding author for this work

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.

Original languageEnglish (US)
Article numbere26493
JournalPediatric Blood and Cancer
Volume64
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Chimerism
Myelodysplastic Syndromes
Hematopoietic Stem Cells
Acute Myeloid Leukemia
Hematopoietic Stem Cell Transplantation
Pediatrics
T-Lymphocytes
Transplants
Recurrence
Graft vs Host Disease

Keywords

  • AML
  • HCT
  • chimerism
  • pediatrics
  • relapse

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Cite this

@article{77eef46d2915440f9c409af1f3538437,
title = "Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant",
abstract = "Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.",
keywords = "AML, HCT, chimerism, pediatrics, relapse",
author = "Larisa Broglie and Irene Helenowski and Jennings, {Lawrence J} and Kristian Schafernak and Duerst, {Reggie E} and Jennifer Schneiderman and Tse, {William T} and Morris Kletzel and Sonali Chaudhury",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/pbc.26493",
language = "English (US)",
volume = "64",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "9",

}

Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant. / Broglie, Larisa; Helenowski, Irene; Jennings, Lawrence J; Schafernak, Kristian; Duerst, Reggie E; Schneiderman, Jennifer; Tse, William T; Kletzel, Morris; Chaudhury, Sonali.

In: Pediatric Blood and Cancer, Vol. 64, No. 9, e26493, 01.09.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early mixed T-cell chimerism is predictive of pediatric AML or MDS relapse after hematopoietic stem cell transplant

AU - Broglie, Larisa

AU - Helenowski, Irene

AU - Jennings, Lawrence J

AU - Schafernak, Kristian

AU - Duerst, Reggie E

AU - Schneiderman, Jennifer

AU - Tse, William T

AU - Kletzel, Morris

AU - Chaudhury, Sonali

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.

AB - Patients with acute myeloid leukemia (AML) who relapse after hematopoietic stem cell transplantation (HCT) have dismal outcomes. Our ability to predict those at risk for relapse is limited. We examined chimerism trends post-HCT in 63 children who underwent HCT for AML or myelodysplastic syndrome (MDS). Mixed T-cell chimerism at engraftment and absence of chronic graft versus host disease (cGVHD) were associated with relapse (P = 0.04 and P = 0.02, respectively). Mixed T-cell chimerism at engraftment was predictive in patients without cGVHD (P = 0.03). Patients with engraftment mixed T-cell chimerism may warrant closer disease monitoring and consideration for early intervention.

KW - AML

KW - HCT

KW - chimerism

KW - pediatrics

KW - relapse

UR - http://www.scopus.com/inward/record.url?scp=85014674706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014674706&partnerID=8YFLogxK

U2 - 10.1002/pbc.26493

DO - 10.1002/pbc.26493

M3 - Article

C2 - 28266766

AN - SCOPUS:85014674706

VL - 64

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 9

M1 - e26493

ER -